Cardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis.
D'Andrea E, Desai RJ, He M, Glynn RJ, Lee H, Weinblatt ME, Kim SC.
J Am Coll Cardiol. 2022 07 05. 80(1):36-46. PMID: 35772915
Instructors
Seoyoung C. Kim
Links
Overview
Seoyoung C. Kim, M.D, Sc.D, M.S.C.E, is an Associate Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital. She is the Director of the Program in Rheumatologic, Immunologic, and Musculoskeletal PharmacoEpidemiology (PRIME).
She is board-certified in Rheumatology, and co-appointed in the Division of Rheumatology, Immunology and Allergy at Brigham and Women’s Hospital. Her research focuses on comparative safety and effectiveness of medications for the rheumatic diseases as well as health services/outcome research in Rheumatology.
Dr. Kim is an Associate Editor for Arthritis Care & Research and ACR Open Rheumatology and has served on a number of Committees for the American College of Rheumatology and the International Society for Pharmacoepidemiology.
BWH DOM Early Career Mentoring Award
Brigham and Women's Hospital
Harvard Catalyst Clinical Research Center Batch Sample Analysis and Assay Validation Award
Harvard Catalyst
Chair's Research Award
Brigham and Women's Hospital, DOM
Henry Kunkel Early Career Investigator Award
American College of Rheumatology
Bibliography
Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records.
Jin Y, Landon JE, Krueger W, Liede A, Desai RJ, Kim SC.
BioDrugs. 2022 Jul. 36(4):521-535. PMID: 35771381
Cardiovascular and Mortality Risk with Intravitreal Vascular Endothelial Growth Factor Inhibitors in Patients with Diabetic Retinopathy.
Roh M, Tesfaye H, Kim SC, Zabotka LE, Patorno E.
Ophthalmol Retina. 2022 Jun 28. PMID: 35777664
Combined Conventional Synthetic Disease Modifying Therapy vs. Infliximab for Rheumatoid Arthritis: Emulating a Randomized Trial in Observational Data.
Barbulescu A, Askling J, Saevarsdottir S, Kim SC, Frisell T.
Clin Pharmacol Ther. 2022 Jun 02. PMID: 35652244
Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) Study.
Khosrow-Khavar F, Desai RJ, Lee H, Lee SB, Kim SC.
Arthritis Rheumatol. 2022 May 29. PMID: 35643956
Risk of malignant melanoma and non-melanoma skin cancer in rheumatoid arthritis patients initiating methotrexate versus hydroxychloroquine: a cohort study.
Lee H, Chen SK, Gautam N, Vine SM, He M, Desai RJ, Weinblatt ME, Glynn RJ, Kim SC.
Clin Exp Rheumatol. 2022 May 10. PMID: 35616586
Risk of Hospitalization for Heart Failure in Patients With Hyperkalemia Treated With Sodium Zirconium Cyclosilicate Versus Patiromer.
Zhuo M, Kim SC, Patorno E, Paik JM.
J Card Fail. 2022 Sep. 28(9):1414-1423. PMID: 35470055
Development of a Medicare Claims-Based Model to Predict Persistent High-Dose Opioid Use After Total Knee Replacement.
Gopalakrishnan C, Desai RJ, Franklin JM, Jin Y, Lii J, Solomon DH, Katz JN, Lee YC, Franklin PD, Kim SC.
Arthritis Care Res (Hoboken). 2022 08. 74(8):1342-1348. PMID: 33450136
Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease.
Kirchgesner J, Desai RJ, Schneeweiss MC, Beaugerie L, Schneeweiss S, Kim SC.
Gut. 2022 09. 71(9):1781-1789. PMID: 35387877
Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents.
Desai RJ, Varma VR, Gerhard T, Segal J, Mahesri M, Chin K, Horton DB, Kim SC, Schneeweiss S, Thambisetty M.
JAMA Netw Open. 2022 04 01. 5(4):e226567. PMID: 35394510